Treatment with the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel significantly improved overall survival compared with bevacizumab and chemotherapy alone for patients with advanced nonsquamous non–small cell lung cancer.
Original Article: Frontline Atezolizumab Regimen Improves Survival in NSCLC
NEXT ARTICLE